Skip Navigation

European Heart Journal 1993 14(Supplement B):16-21; doi:10.1093/eurheartj/14.suppl_B.16
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Suryapranata, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suryapranata, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

Coronary haemodynamics and vasodilatory profile of a potassium channel opener in patients with coronary artery disease

H. Suryapranata

Department of Cardiology, Hospital de Weezenlanden Zwolle, The Netherlands

Correspondence to: Harry Suryaprantata, MD, PhD, FESC, Department of cadiology, Hospital de Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, The Netherlands.

Previous studies have indicated that nicorandil reduces both preload and afterload, clearly distinguishing nicorandil from conventional nitrates, whose predominant action is that of preload reduction. In association with the decrease in afterload following nicorandil, the contractile responses during isovolumic contraction and relaxation improved significantly, indicating that nicorandil does not demonstrate negative inotropic actions. Furthermore, despite a marked decrease in mean aortic pressure after nicorandil, coronary sinus blood flow remains unchanged. Therefore, coronary vasodilatation must have taken place, while myocardial oxygen consumption decreased significantly. The vasodilatory action of nicorandil on the epicardial coronary artery has also been demonstrated in our previous study. Nicorandil, at a dose of either 20 or 40 mg, induces a significant increase in coronary artery diameter favourably by acting not only on the non-stenotic but also on the stenotic coronary segments.

In our recent study, the effects of intracoronary nicorandil (6µ. kg) and isosorbide dinitrate (2 mg) on the epicardial coronary arteries were investigated in patients undergoing coronary angioplasty. In non-stenotic coronary artery segments, the mean coronary diameter increased significantly after either nicorandil (+ 12%) or isosorbide dinitrate (+ 17%). In stenotic segments, however, increase in the diameter of the obstructed segment by 20% after intracoronary nicorandil was much more pronounced when compared to that of 8% after isosorbide dinitrate. There was a significant additional increase of 13% in the diameter of the obstructed segment when nicorandil was administered following isosorbide dinitrate, while no such additional effect was observed when isosorbide dinitrate was given after nicorandil.

In summary, the potential advantage of nicorandil is that, at anti-anginal doses, it has a coronary vasodilating action combined with a balanced peripheral vasodilatation, which leads to a decrease in both preload and afterload. Therefore, nicorandil affects two of the main haemodynamic determinants of oxygen demand without impairing myocardial contractility. More importantly, both intracoronary nicorandil and isosorbide dinitrate induce significant vasodilatation in non-stenotic coronary arteries, but nicorandil appears to be more potent than isosorbide dinitrate in dilating stenotic coronary segments.

Key Words: Haemodynamics • nicorandil • vasodilatory action.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
P. J de Kam, A. A Voors, F. Fici, D. J van Veldhuisen, and W. H van Gilst
Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2004; 5(4): 161 - 168.
[Abstract] [PDF]


Home page
StrokeHome page
O. Fustinoni
Editorial Comment--Left Ventricular Hypertrophy: An Unseemly Risk Factor for Stroke?
Stroke, October 1, 2003; 34(10): 2385 - 2386.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Booke, R. Waurick, H. Van Aken, H.-G. Bone, Andreas Meissner, T. Prien, and J. Meyer
Effects of sympathetic nerve blockade on vasoconstrictive properties of nitric oxide synthase inhibition in sheep
Cardiovasc Res, October 1, 1997; 36(1): 111 - 117.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.